Brawn Biotech net profit falls 35% in Q1FY26 to ₹15.44 lakh
Brawn Biotech's Q1FY26 net profit fell 35% to ₹15.44 lakh despite a 5.6% rise in operating income to ₹621.74 lakh. The decline was attributed to a sharp increase in expenses, particularly inventory changes. The board approved the results and recommended new statutory auditors.
*this image is generated using AI for illustrative purposes only.
Brawn Biotech reported a net profit of ₹15.44 lakh for the quarter ended June 30, 2026, down from ₹23.60 lakh in the corresponding period of FY25. While total income from operations grew to ₹621.74 lakh from ₹588.86 lakh year-ago, the profitability contraction highlights pressure on operating efficiency.
The board of directors approved the unaudited financial results on August 13, 2026, following recommendations from the Audit Committee. The company also recommended the appointment of M/s G D S M and Co as statutory auditors for a five-year term, subject to shareholder approval at the upcoming Annual General Meeting (AGM).
Financial Performance
Total income from operations increased by 5.6% year-on-year. However, total expenses rose sharply to ₹606.30 lakh from ₹565.26 lakh in Q1FY25, largely due to significant changes in inventory levels.
| Metric | Q1FY26 (₹ in Lacs) | Q1FY25 (₹ in Lacs) | Change |
|---|---|---|---|
| Total Income from Operations | 621.74 | 588.86 | +5.6% |
| Total Expenses | 606.30 | 565.26 | +7.3% |
| Net Profit | 15.44 | 23.60 | -34.6% |
| EPS (Basic) | ₹0.52 | ₹0.89 | -41.6% |
What the Numbers Show
A divergence between revenue growth and expense inflation is visible in the data. While revenue rose by just over 5%, total expenses climbed by over 7%. This was primarily driven by a surge in "Change in inventories" to ₹295.34 lakh from ₹104.92 lakh in the prior year quarter. This indicates that a significant portion of the cost outflow was tied to inventory accumulation rather than direct consumption or sales, compressing the profit from operations before tax to ₹15.44 lakh from ₹23.60 lakh.
Corporate Actions
Alongside the financial results, the board approved the convening of the 41st Annual General Meeting via Video Conferencing/Other Audio-Visual Means on September 29, 2026. The draft notice for the AGM will be dispatched to shareholders shortly.
The company engaged Rajiv Udai & Associates to conduct the limited review of the interim financial information. The CFO certificate confirmed no material changes in internal controls or instances of fraud during the quarter.
Historical Stock Returns for Brawn Biotech
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -4.98% | -2.04% | +9.55% | +14.72% | +11.82% | 0.0% |
Will Brawn Biotech's aggressive inventory accumulation in Q1FY26 translate into higher sales volumes in subsequent quarters, or does it signal potential overstocking risks?
How might the appointment of M/s G D S M and Co as statutory auditors for a five-year term impact the company's financial reporting transparency and investor confidence?
Given the 34.6% drop in net profit despite revenue growth, what specific cost-control measures is management planning to implement to reverse the margin compression trend?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
